Orphan Drug Status Granted to Potential Polycystic Kidney Disease Treatment
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations of the PKD1 and PKD2 genes.
ADPKD
Tolvaptan Lowers Kidney Stone Risk in ADPKD
Tolvaptan improves the urinary lithogenic risk profile of patients with autosomal dominant polycystic kidney disease, according to researchers.
Bardoxolone Gets Orphan Drug Status for Autosomal Dominant Polycystic Kidney Disease
The FDA has granted bardoxolone methyl (bardoxolone; Reata Pharmaceuticals) Orphan Drug designation for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Most Common ADPKD Imaging Modality Is Computed Tomography
Nearly half of patients with autosomal dominant polycystic kidney disease receive at least 1 CT scan over 2 years, study finds.
Iron Profile Differs for Hemodialysis Patients With ADPKD
Investigators found a U-shaped curve of mortality against ferritin/TSAT levels in patients without autosomal dominant polycystic kidney disease, but not in those with the disease.
Bardoxolone Shows Promise for ADPKD
In a phase 2 trial that enrolled 31 patients with autosomal dominant polycystic kidney disease, treatment with bardoxolone resulted in a significant increase in kidney function.
-
Loading...
-
Loading...
Next post in ERA-EDTA Congress
